INS and type 1 diabetes mellitus: This is the case for trials of disease-modifying therapy (DMT) in type 1 diabetes (T1D) aiming to preserve endogenous pancreatic beta cell function, as there is a wealth of natural history data on the loss of insulin secretion over time measured by the C-peptide response to a mixed meal tolerance test (MMTT)4–18.